免疫萬公司
US ˙ NasdaqGS ˙ US45258J1025

SecurityIMVT / Immunovant, Inc.
InstitutionONEQ - Fidelity Nasdaq Composite Index Tracking Stock
Latest Disclosed Ownership40,773 shares
Latest Disclosed Value $ 605,479
ONEQ - Fidelity Nasdaq Composite Index Tracking Stock reports 0.49% increase in ownership of IMVT / Immunovant, Inc.

On July 24, 2025 - ONEQ - Fidelity Nasdaq Composite Index Tracking Stock filed a NPORT-P form disclosing ownership of 40,773 shares of Immunovant, Inc. (US:IMVT) valued at $605,479 USD as of May 31, 2025. The entity filed a previous NPORT-P on April 25, 2025 disclosing 40,573 shares of Immunovant, Inc.. This represents a change in shares of 0.49% during the quarter. The current value of the position is $1,268,448 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-07-24 2025-05-31 NP IMMUNOVANT EC US45258J1025 40,773 200 0.49 605 -27.54 0.0080
2025-04-25 2025-02-28 NP IMMUNOVANT EC US45258J1025 40,573 1,080 2.73 836 -24.98 0.0113
2025-01-27 2024-11-30 NP IMMUNOVANT EC US45258J1025 39,493 280 0.71 1,114 -8.09 0.0151
2024-10-29 2024-08-31 NP IMMUNOVANT EC US45258J1025 39,213 380 0.98 1,212 22.94 0.0180
2024-07-26 2024-05-31 NP IMMUNOVANT EC US45258J1025 38,833 500 1.30 986 -27.31 0.0156
2024-04-24 2024-02-29 NP IMMUNOVANT EC US45258J1025 38,333 4,014 11.70 1,356 0.97 0.0226
2024-01-24 2023-11-30 NP IMMUNOVANT EC US45258J1025 34,319 54 0.16 1,343 72.49 0.0258
2023-10-27 2023-08-31 NP IMMUNOVANT EC US45258J1025 34,265 540 1.60 778 9.89 0.0152
2023-07-26 2023-05-31 NP IMMUNOVANT EC US45258J1025 33,725 108 0.32 709 20.61 0.0153
2023-04-27 2023-02-28 NP IMMUNOVANT EC US45258J1025 33,617 810 2.47 587 36.51 0.0144
2023-01-26 2022-11-30 NP IMMUNOVANT EC US45258J1025 32,807 14,046 74.87 430 51.41 0.0108
2021-07-22 2021-05-31 NP IMMUNOVANT EC US45258J1025 18,761 72 0.39 284 -3.40 0.0071
2021-04-23 2021-02-28 NP IMMUNOVANT EC US45258J1025 18,689 1,080 6.13 295 -66.05 0.0077
2021-01-20 2020-11-30 NP IMMUNOVANT EC US45258J1025 17,609 17,609 866 0.0259
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.